8-K: Vicarious Surgical Faces NYSE Delisting, Shifts to OTCID

Vicarious Surgical Inc. announced its Class A common stock will be delisted from the NYSE due to falling below the minimum market capitalization requirement, with trading suspended and a move to the OTCID market tier.

Summary

• Received a notice from the New York Stock Exchange (NYSE) on March 3, 2026, regarding the commencement of delisting proceedings for its Class A common stock.
• Trading of the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026.
• The delisting is due to the Company falling below the NYSE's continued listing standard, which requires maintaining an average global market capitalization of at least $15,000,000 over a consecutive 30 trading day period.
• The NYSE will apply to the Securities and Exchange Commission (SEC) to delist the Common Stock upon completion of all applicable procedures, including any appeal by the Company.
• The Company is currently evaluating whether to appeal the delisting determination, with an appeal deadline of ten business days from receipt of the notice.
• Received approval for its application to have the Common Stock quoted on the OTCID market tier (OTCID) operated by The OTC Markets Group, Inc.
• The Common Stock is expected to commence quotation on the OTCID at the open of business on March 4, 2026, under the current trading symbol of RBOT.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, reflecting significant financial underperformance and a loss of investor confidence, despite the mitigation of moving to OTCID. The move to a less liquid market and the associated risks are substantial.

Positives

• Approval received for quotation on the OTCID market tier, providing an alternative trading venue for the Common Stock.

Negatives

• Delisting from the New York Stock Exchange (NYSE) due to failure to meet continued listing standards.
• Suspension of trading on the NYSE after market close on March 3, 2026.
• Failure to maintain an average global market capitalization of at least $15,000,000 over a consecutive 30 trading day period.
• The OTCID is a significantly more limited market than the NYSE, which will result in less liquidity for existing and potential holders of the Common Stock.
• Quotation on an OTC market could further depress the trading price of the Common Stock.
• Delisting could negatively impact the Company's ability to raise equity financing and access public capital markets.
• The Company's ability to provide equity incentives to its employees could be impaired.

Risks

• Future fluctuations in the Company's market capitalization and stockholders' equity.
• The OTCID is a significantly more limited market than the NYSE, which will result in a less liquid market for existing and potential holders of the Common Stock.
• Quotation on any OTC market could further depress the trading price of the Common Stock.
• No assurance that the Common Stock will continue to trade on the OTCID market.
• No assurance that broker-dealers will provide and continue to provide public quotes of the Common Stock on the OTCID market.
• No assurance that the trading volume of the Common Stock will be sufficient to provide for an efficient trading market.
• The suspension and/or delisting of the Company's common stock from the NYSE could negatively impact the Company's ability to raise equity financing.
• Delisting could impact the Company's ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets.
• Delisting could impair the Company's ability to provide equity incentives to its employees.
• Risks related to the approval, commercialization, and adoption of the Company's initial product candidates and the success of its single-port surgical robot.
• Changes in applicable laws or regulations and the Company's ability to obtain and maintain regulatory approval for its products.
• The Company's ability to compete with other companies in the surgical robotics market.
• Economic downturns, political and market conditions and their potential to adversely affect the Company's business, financial condition and results of operations.
• The Company's intellectual property rights and its ability to protect or enforce those rights.

Future Outlook

The Company is evaluating whether to appeal the delisting determination. It expects its Common Stock to commence quotation on the OTCID market tier on March 4, 2026. The company also highlights risks associated with the OTCID market, including reduced liquidity and potential further depression of the stock price, and the potential negative impact on its ability to raise future financing and provide equity incentives.

Management Comments

• The Company is evaluating whether to appeal the delisting determination.
• The Company expects the Common Stock will commence quotation on the OTCID at the open of business on March 4, 2026 under the current trading symbol of RBOT.

Industry Context

StockSavvy.ai notes that delisting from a major exchange like the NYSE to an OTC market tier is a significant setback for any publicly traded company, often signaling severe financial distress or a failure to meet fundamental listing requirements. For a surgical robotics company like Vicarious Surgical, which relies heavily on investor confidence and access to capital for R&D and commercialization, this move could severely hinder its ability to compete with well-capitalized industry leaders and emerging innovators in the highly competitive medical technology sector.

Comparison to Industry Standards

• Delisting from the NYSE due to market capitalization falling below $15 million is a clear indicator of underperformance compared to typical public company standards for major exchange listings.
• Major surgical robotics companies like Intuitive Surgical (ISRG) maintain market capitalizations in the tens of billions, demonstrating robust investor confidence and market presence, a stark contrast to Vicarious Surgical's current situation.
• Smaller, emerging medical device companies typically aim to maintain listing on major exchanges to ensure liquidity and access to broader investor pools, which Vicarious Surgical has now lost, placing it at a disadvantage compared to peers still listed on primary exchanges.

Stakeholder Impact

• Shareholders: Will experience reduced liquidity and potentially further depressed trading price for their Common Stock due to the move to the OTCID market. The ability to sell shares efficiently will be diminished.
• Employees: The Company's ability to provide equity incentives to its employees could be impaired, potentially affecting morale and retention.
• Creditors/Investors: The Company's ability to raise future equity financing will be negatively impacted, making it harder to secure capital for operations and growth.

Next Steps

• The Company is evaluating whether to appeal the NYSE's delisting determination, which must be made within ten business days from receipt of the Notice.
• The Common Stock is expected to commence quotation on the OTCID market tier at the open of business on March 4, 2026.
• The NYSE will apply to the SEC to delist the Common Stock upon completion of all applicable procedures, including any appeal by the Company.

Key Dates

Recommendation

The delisting from the NYSE due to failing to meet minimum market capitalization requirements is a severe negative signal, indicating significant financial distress and loss of investor confidence. The move to the less liquid OTCID market will further reduce the stock's appeal and likely depress its price. The company's ability to raise future capital and attract talent is also severely compromised. Investors should consider exiting their positions to avoid further losses.

Keywords

Vicarious Surgical, RBOT, NYSE delisting, OTCID, surgical robotics, market capitalization, SEC filing, robotics technology, medical device, corporate governance